Chapter 440 - 263: Mastering the Full Skill Tree of the Liver Tumor Field
Chapter 440: Chapter 263: Mastering the Full Skill Tree of the Liver Tumor Field
Afterward, this group of personal students would go on to pursue even greater endeavors and ideals.
As the intensive training with Wu Ting and the four directors progressed, the number of patients who had undergone surgery and been successfully discharged began to grow.
The next step was to conduct continuous post-operative follow-ups to establish a complete, full-cycle treatment process.
The four directors’ confidence in Wu Ting’s project grew stronger and stronger!
They were all looking forward to the end of the intensive training, when they would pass Wu Ting’s assessment, return to their respective departments, and truly begin dedicating themselves to the project.
After finishing a day of study, Chen Bofeng returned to his hotel. He ordered a foot massage service, turned on the TV, and started playing a video from earlier that day demonstrating Wu Ting’s negative immunomodulatory therapy.
He watched the video and took notes, all while a technician gave him a foot wash and massage.
Just as Chen Bofeng was getting absorbed in his work, his phone rang.
Chen Bofeng saw it was his old classmate, Han Shun, the Director of Hepatic Tumor Surgery at Qinghe City’s Hospital 302.
"Bo Feng, I have some good news. I’ve successfully passed the review by Professor Edwards’s team and secured authorization for the first batch of Neutrino instruments."
"We signed the cooperation agreement today, and I’m heading back to the country tomorrow. Once I’m back, I’ll find you for a chat."
"I think you might have really misjudged the situation this time, completely turning your back on the mainstream revolutionary technology for primary liver cancer caused by hepatitis B."
"But it’s not too late. Professor Edwards is planning to convene a special meeting of the International Liver Cancer Association at the end of the month. The goal is to form an International HBV-Related Primary Liver Cancer Treatment Research Group centered around Neutrino Technology. As a representative of one of the first partner institutions, I’ll be able to become an executive council member in the first term."
"When the time comes, if you’re willing, I can recommend your hospital to be included in the second batch of partner institutions and invite you to serve as a council member."
"Bo Feng, this Neutrino Technology truly has enormous potential. As soon as the Neutrino instruments are delivered to our hospital and finish installation and calibration, I’m going to lead my team in starting the first phase of clinical trials."
"This is the most advanced technology in the world; it’s going to bring tremendous prestige and influence. Bo Feng, if you miss out on the second batch, it’ll be very difficult to catch up later."
According to Professor Edwards’s strategy, the first batch was carefully selected by his team and consisted of nationally representative medical institutions from various countries.
The second batch would be recommended by the first-term council members and would consist of mainstay, pillar-like institutions, essentially covering the remainder of the top-tier medical facilities.
As for the third batch, one would have to get in line, go through a complex application process, and pass multiple layers of approval just for a chance.
By that point, Neutrino Technology would have already been rolled out to all the necessary partner institutions, and the first- and second-tier teams would have long since produced results.
Han Shun was truly full of confidence in this technology, and he didn’t want Chen Bofeng to miss this opportunity.
However, despite Han Shun’s persuasion, Chen Bofeng remained completely unmoved.
Instead, he asked Han Shun two questions.
"Old Han, based on the current results of the Neutrino therapy, doesn’t it still require combined antiviral treatment to even have a possibility of a complete cure?"
"And at present, can this therapy only target early to mid-stage primary liver cancer caused by hepatitis B, while for mid to late-stage cases, it can only offer palliation and control?"
Han Shun confirmed both of Chen Bofeng’s points.
"Bo Feng, any technology is bound to be imperfect and have limitations when it’s first created. But isn’t that precisely where our opportunity lies?"
Chen Bofeng signaled for the massage technician to be gentler and then expressed his final thoughts to Han Shun.
"Old Han, thank you. I understand what you mean."
"But this time, I’m preparing to try a path of completely independent research and development. A path that I believe is the true, viable, and comprehensive way to a complete cure for primary liver cancer caused by hepatitis B."
"I believe that before long, at this year’s annual meeting of the Medical Association’s Surgical Branch, we will be able to present our Phase Three results."
After finishing his chat with Han Shun, Chen Bofeng put down his phone and gestured for the technician to continue, this time with a bit more force.
At the same time, he resumed the instructional video and turned up the volume.
Far away in the Southern Country, preparing to return home, Han Shun had, of course, looked into the research Chen Bofeng was actually conducting. He had also seen the press coverage from their conference.
However, when compared to the mainstream therapy from the Edwards team—a project that united the world’s top medical institutions and pharmaceutical groups—Han Shun simply didn’t believe Chen Bofeng’s research group could compete. Composed of just a few outmatched hospitals and led by a young man not yet thirty, he felt they stood no chance against the Neutrino project.
’Oh, Bo Feng, Bo Feng... Doing things this way, you’re only going to cause the entire delta region to fall completely behind the rest of the country in the field of HBV-related primary liver cancer treatment.’
Han Shun planned to begin the relevant clinical trials as soon as he returned to the country and the instruments arrived.
This time, a total of six hospitals in the country had received authorization from Professor Edwards.
They were: Qinghe City’s Hospital 302, Yacheng Hospital, Xidu Liver and Gallbladder Hospital, Guan Province University Affiliated Hospital, Lin Province Pinfan Hospital, and Qinghe City You’an Hospital.
As for the list for the second batch, recommendations would be made and a final decision reached on the day the International HBV-Related Primary Liver Cancer Treatment Research Group was established.
Surprisingly, Qinghe City Jiuhua Hospital was not on the list of the first batch this time!
...
...
Just as the results from the Edwards team were causing a worldwide sensation...